By Landon Gray
A novel broad-spectrum, orally administered antiviral candidate, CC-42344 (Cocrystal Pharma), for the treatment of pandemic and seasonal influenza A, has shown promising data that support the potential for once-daily dosing.
The randomized, double-controlled, dose-escalating phase 1 study is designed to evaluate the safety, tolerability and pharmacokinetics (PK) of CC-42344 in healthy adults in Australia. Fifty-six healthy men and women who are between 18 and 55 years of age were